Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Health Catalyst, Inc. (HCAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed provider of data and analytics technology and services to healthcare organizations, Health Catalyst uses these filings to report financial performance, governance decisions, and material corporate events.
Investors researching HCAT can review quarterly earnings information furnished on Form 8-K under Item 2.02, where Health Catalyst attaches its press releases and earnings release summaries for periods such as the quarters ended June 30 and September 30, 2025. These materials include segment revenue for Technology and Professional Services, gross profit and margins, adjusted gross profit, adjusted gross margin, adjusted EBITDA, and reconciliations of non-GAAP measures to the most directly comparable GAAP metrics.
Additional Form 8-K filings disclose executive and board changes under Item 5.02, such as the appointment of a President and Chief Operating Officer, the CEO’s planned retirement date, and the addition of new board members along with their compensation arrangements. Filings also summarize outcomes of the annual meeting of stockholders under Item 5.07, including director elections, ratification of the independent registered public accounting firm, and advisory votes on executive compensation and board declassification.
Beyond current reports on Form 8-K, Health Catalyst’s periodic reports on Forms 10-K and 10-Q, referenced in its press releases, contain detailed discussions of risk factors, management’s analysis of financial condition and results of operations, and disclosures about items such as stock-based compensation, acquisition-related costs, restructuring charges, and lease-related items.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain the key points of lengthy documents, such as annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K). Users can quickly see what changed in a filing, how segment results evolved, and which governance or compensation decisions were disclosed, while still having direct access to the full SEC documents for deeper review.
Health Catalyst, Inc. (HCAT) filed a Form 144 notifying the proposed sale of 3,663 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $12,317.57. The shares were acquired the same day as restricted stock from the issuer as compensation. The filing also discloses a prior sale by the same person on 06/02/2025 of 3,802 restricted shares for $13,819.51. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Health Catalyst, Inc. reported revenue of $160.1 million for the six months ended June 30, 2025, up from $150.6 million a year earlier, driven by higher recurring technology revenue of $104.4 million (vs. $94.6 million). Despite revenue growth, operating costs and a $28.8 million goodwill impairment contributed to a wider six-month net loss of $64.7 million, or $0.94 per share, compared with a $34.1 million loss a year ago.
Cash and cash equivalents declined sharply to $50.7 million from $249.6 million at year-end, reflecting cash used to settle long-term obligations including the full cash settlement of convertible senior notes and acquisition activity (notably the Upfront acquisition with $80.0 million consideration). Total assets fell to $616.2 million and total liabilities to $268.6 million, leaving stockholders' equity of $347.5 million.
Form 3 overview – Health Catalyst, Inc. (HCAT): On 06/25/2025, Chief Technology & Product Officer David Coy Ross filed an initial statement of beneficial ownership. The filing discloses direct ownership of 207,579 common shares, consisting of previously issued stock plus multiple tranches of restricted stock units (RSUs) granted under the 2019 Stock Option and Incentive Plan. The RSUs follow customary quarterly-vesting schedules, with the largest award (90,000 RSUs) beginning to vest on 12/01/2025 (33.33%) and the balance in eight equal quarterly installments. No derivative securities, purchases, or sales were reported; the Form 3 simply records the officer’s existing equity position as required under Section 16(a). The disclosure signals equity alignment between the newly reported executive and shareholders but does not by itself imply any immediate financial impact on HCAT.